周兰教授从痰瘀互结论治中晚期卵巢癌的经验  

Director Zhou Lan ' s experience in treating middle and late stage ovarian cancer basedon the conclusion of phlegm and blood stasis interaction

作　　者：程慧娟 周兰 CHENG Huijuan;ZHOU Lan(Department of Traditional Chinese Medicine,the First Affiliated Hospital of Bengbu Medical University,Bengbu,Anhui 233004,China)

机构地区：[1]蚌埠医科大学第一附属医院中医科,安徽蚌埠233004

出　　处：《中华全科医学》2025年第2期305-308,共4页Chinese Journal of General Practice

基　　金：2022年度中央财政中医药事业传承与发展专项资金项目(Z155080000004)。

摘　　要：卵巢癌是女性高发恶性肿瘤,因病因尚不明确,且缺乏早期发现的有效方法,临床确诊时多为晚期。晚期卵巢癌复发率高,生存率低。中晚期卵巢癌的主要治疗方式是手术和化疗,可根据患者对铂类药物的敏感性分类应用铂类或非铂类药物化疗,联合抗血管生成靶向药物,根据基因检测可考虑多腺苷二磷酸核糖聚合酶(PARP)抑制剂、免疫治疗。卵巢癌中医属“癥瘕”“积聚”,周兰教授认为该病的病因病机为痰瘀互结,以活血化瘀、化痰散结为基本方法,配合清热解毒、疏肝行气、健脾养血、调摄冲任、滋阴润燥等法,治疗中晚期卵巢癌及手术、化疗、靶向、PARP药物应用后并发症的中医治疗,大大延长了患者的生存期,提高了患者的生存质量,临床疗效佳。Ovarian cancer is a malignant tumor with a high incidence in women.Due to the unclear etiology and the lack of effective methods for early detection,it is mostly diagnosed in the late stage.The recurrence rate of advanced ovarian cancer is high and the survival rate is low.The main treatment modalities for advanced ovarian cancer are surgery and chemotherapy.Platinum or non-platinum chemotherapy can be classified according to the sensitivity of patients to platinum drugs,combined with anti-angiogenesis targeted drugs,and poly(ADP-ribose)polymerase(PARP)inhibitors and immunotherapy can be considered according to genetic testing.The traditional Chinese medicine of ovarian cancer refers to"lump"and"accumulation".Director Zhou Lan believes that the cause and pathogenesis of this disease are the interformation of phlegm and blood stasis.Combining the basic methods of promoting blood circulation and removing blood stasis with the methods of clearing heat and detoxification,soothing the liver and promoting qi,invigorating the spleen and nourishing the blood,regulating Chong Ren,nourishing Yin and moistening dryness,the traditional Chinese medicine treatment of the complications after surgery,chemotherapy,targeting,and PARP.The survival period of patients was greatly extended,the quality of life of patients was improved,and the clinical effect was good.

关 键 词：卵巢癌 痰瘀互结 

分 类 号：R737.31[医药卫生—肿瘤] R273[医药卫生—临床医学]